Hydrapres® is indicated for the treatment of moderate to severe hypertension in adults in combination with other antihypertensive agents.
Due to their complementary mechanisms of action, the combination of hydralazine with beta-blockers and diuretics makes it possible to achieve antihypertensive efficacy at lower doses and to reduce some effects of hydralazine, such as reflex tachycardia and edema.
Hydrapres® is also indicated for moderate to severe chronic congestive heart failure as adjunctive medication together with long-acting nitrates in patients who do not respond adequately to conventional treatment with diuretics and digitalis.
FT Hydrapres tablets FT Hydrapres injectable
It is supplied in 20 mg lyophilised powder (5 ampoule per box) or 50 mg and 25 mg tablets (30 tablets per box).
